Oslo, March 11, 2024 - Observe Medical ASA (the "Company" or "Observe Medical")
announces that the Group, via its UK distributor C&P Medical, has been awarded
onto the Scottish NHS Urology Framework with Unometer[TM ]500. This is a 3 year
contract until end of March 2027, effective from April 2024.

NHS Scotland consists of 14 geographically based local NHS boards with over 180
individual NHS hospitals containing more than 13,000 available staffed beds for
acute specialities.NHS Scotland has historically ordered more than 150,000 units
annually of Unometer[TM] of a total UK market of approximately 800,000 units
annually. Anticipating a continuation of this strong demand, this new Framework
agreement holds the potential to generate annual revenues exceeding NOK 13
million.

Building on the recent announcement made on September 11, 2023, regarding
Observe Medical's acquisition of trademarks and other intellectual property
rights for the UnometerT and Abdo-PressureT products, we are thrilled to unveil
this major agreement with NHS Scotland for distribution of our UnometerT 500
product. This marks a substantial milestone in the ongoing development of the
UnometerT business, which has traditionally generated annual revenues exceeding
NOK 200 million.

"I am proud of the entire Observe Medical team who, through dedicated work, have
enabled us to be in a position to deliver Unometer[TM ]500 products to NHSSC. I
would also like to applaud our UK distributor, C&P Medical, who through their
expertise have been crucial during this process. This agreement underscores the
strength and market position of high-quality products such as our
Unometer[TM ]portfolio", said Jørgen Mann, Interim CEO at Observe Medical.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Terje Bakken, Chairman Observe Medical
Mobile: +47 934 33 321
E-mail: tb@reitenco.no

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care,
in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik,
Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In
addition, Observe Medical has a direct sale organization in the Nordics and a
distributor network internationally.

Further information is available at www.observemedical.com.